Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Martins

Showing results (301-310 of 313) with videos related to

Pageof 32
Sort By:
Pharmaceutics|August 28, 2025
Bioactive Chalcone-Loaded Mesoporous Silica KIT-6 Nanocarrier: A Promising Strategy for Inflammation and Pain Management in ZebrafishMaria Kueirislene Amâncio Ferreira, Francisco Rogenio Silva Mendes, Emmanuel Silva Marinho, et al.
Frontiers in Genetics|April 12, 2024
Comparison of ddRADseq and EUChip60K SNP genotyping systems for population genetics and genomic selection in <i>Eucalyptus dunnii</i> (Maiden)Natalia Cristina Aguirre, Pamela Victoria Villalba, Martín Nahuel García, et al.
The Journal of Pediatrics|September 22, 2009
Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiencesAna Maria Martins, Vânia D'Almeida, Sandra Obikawa Kyosen, et al.
The Journal of Pediatrics|September 22, 2009
Guidelines for the management of mucopolysaccharidosis type IAna Maria Martins, Ana Paula Dualibi, Denise Norato, et al.
Blood Cells, Molecules & Diseases|April 28, 2019
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.
Blood Cells, Molecules & Diseases|April 23, 2018
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.
Arquivos Brasileiros De Cardiologia|March 9, 2022
Clinical, Laboratory, and Imaging Profile in Patients with Systemic Amyloidosis in a Brazilian Cardiology Referral CenterFábio Fernandes, Aristóteles Comte de Alencar Neto, Bruno Vaz Kerges Bueno, et al.
Endocrine Oncology (Bristol, England)|January 17, 2025
NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirationsPo Hien Ear, Ilaria Marinoni, Talya Dayton, et al.
Molecular Genetics and Metabolism|March 29, 2013
Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VIDafne D G Horovitz, Tatiana S P C Magalhães, Angelina Acosta, et al.
Genetics and Molecular Biology|June 4, 2011
Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatmentRoberto Giugliani, Andressa Federhen, Maria Verônica Muñoz Rojas, et al.
Pageof 32

Showing results (301-310 of 313) with videos related to

Sort By:
Pageof 32
Pharmaceutics|August 28, 2025
Bioactive Chalcone-Loaded Mesoporous Silica KIT-6 Nanocarrier: A Promising Strategy for Inflammation and Pain Management in ZebrafishMaria Kueirislene Amâncio Ferreira, Francisco Rogenio Silva Mendes, Emmanuel Silva Marinho, et al.
Frontiers in Genetics|April 12, 2024
Comparison of ddRADseq and EUChip60K SNP genotyping systems for population genetics and genomic selection in <i>Eucalyptus dunnii</i> (Maiden)Natalia Cristina Aguirre, Pamela Victoria Villalba, Martín Nahuel García, et al.
The Journal of Pediatrics|September 22, 2009
Guidelines to diagnosis and monitoring of Fabry disease and review of treatment experiencesAna Maria Martins, Vânia D'Almeida, Sandra Obikawa Kyosen, et al.
The Journal of Pediatrics|September 22, 2009
Guidelines for the management of mucopolysaccharidosis type IAna Maria Martins, Ana Paula Dualibi, Denise Norato, et al.
Blood Cells, Molecules & Diseases|April 28, 2019
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.
Blood Cells, Molecules & Diseases|April 23, 2018
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1Pramod K Mistry, Manisha Balwani, Hagit N Baris, et al.
Arquivos Brasileiros De Cardiologia|March 9, 2022
Clinical, Laboratory, and Imaging Profile in Patients with Systemic Amyloidosis in a Brazilian Cardiology Referral CenterFábio Fernandes, Aristóteles Comte de Alencar Neto, Bruno Vaz Kerges Bueno, et al.
Endocrine Oncology (Bristol, England)|January 17, 2025
NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirationsPo Hien Ear, Ilaria Marinoni, Talya Dayton, et al.
Molecular Genetics and Metabolism|March 29, 2013
Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VIDafne D G Horovitz, Tatiana S P C Magalhães, Angelina Acosta, et al.
Genetics and Molecular Biology|June 4, 2011
Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatmentRoberto Giugliani, Andressa Federhen, Maria Verônica Muñoz Rojas, et al.
Pageof 32